W2O acquisitions continue as it buys Radius Digital ScienceW2O has made its third acquisition in recent months, buying Radius Digital Science, a New Jersey-based scientific creative Share XW2O acquisitions continue as it buys Radius Digital Sciencehttps://pharmaphorum.com/news/w2o-radius-digital-science/
Mavenclad helps Merck shrug off Rebif decline in MSAccelerating sales of Merck KGaA’s oral multiple sclerosis therapy Mavenclad helped the company to a double-digit rise in Share XMavenclad helps Merck shrug off Rebif decline in MShttps://pharmaphorum.com/news/mavenclad-helps-merck-shrug-off-rebif-decline-in-ms/
Claire Gillis wins Women in Marketing health leadership prizeWPP’s health practice international CEO Claire Gillis picked up the inaugural healthcare marketing leadership prize at last night’s Share XClaire Gillis wins Women in Marketing health leadership prizehttps://pharmaphorum.com/news/claire-gillis-women-in-marketing-award/
First Rituxan biosimilar Truxima set to make its debut in USBiosimilar competition to Roche’s big-selling Rituxan has arrived in the US, with Teva gearing up to launch its Share XFirst Rituxan biosimilar Truxima set to make its debut in UShttps://pharmaphorum.com/news/first-rituxan-biosimilar-truxima-set-to-makes-its-debut-in-us/
Open Health merges with HEOR and market access firm PharmeritOpen Health has joined forces with health economics and outcomes research (HEOR) company Pharmerit International in a move Share XOpen Health merges with HEOR and market access firm Pharmerithttps://pharmaphorum.com/news/open-health-merger-heor-pharmerit/
Takeda nets $660m from product selloff to Germany’s StadaTakeda has divested another block of products it views as lying outside its main focus, selling various drugs Share XTakeda nets $660m from product selloff to Germany’s Stadahttps://pharmaphorum.com/news/takeda-nets-660m-from-product-selloff-to-germanys-stada/
Shingrix and Trelegy shield GSK from Advair falloutGlaxoSmithKline is expecting flat earnings this year, having earlier forecast a decline, as rising sales of new drugs Share XShingrix and Trelegy shield GSK from Advair fallouthttps://pharmaphorum.com/news/gsk-advair-shingles-vaccine-trelegy/
J&J refutes FDA findings on asbestos in talcJohnson & Johnson has rejected an assertion by the FDA that asbestos had been found in one of Share XJ&J refutes FDA findings on asbestos in talchttps://pharmaphorum.com/news/jj-refutes-fda-findings-on-asbestos-in-talc/
Vyndaqel romps away in US, spurring earnings hike from PfizerPfizer’s new drug for a rare heart disease – Vyndaqel – has shattered analysts’ sales forecasts in its Share XVyndaqel romps away in US, spurring earnings hike from Pfizerhttps://pharmaphorum.com/news/vyndaqel-romps-away-in-us-spurring-earnings-hike-from-pfizer/
Allergan pays $750m to avoid Alzheimer’s drug lawsuitAllergan has agreed to pay $750 million to settle lawsuits in the US brought by direct purchasers of Share XAllergan pays $750m to avoid Alzheimer’s drug lawsuithttps://pharmaphorum.com/news/allergan-pays-750m-to-avoid-alzheimers-drug-lawsuit/
Intouch Group opens two California officesIntouch Group has announced it is further expanding its US footprint with the opening of two new offices Share XIntouch Group opens two California officeshttps://pharmaphorum.com/sales-marketing/intouch-group-opens-two-california-offices/
AZ’s new cancer drugs drive another stellar quarterAstraZeneca has raised its sales guidance of the year once again as its trio of new cancer drugs Share XAZ’s new cancer drugs drive another stellar quarterhttps://pharmaphorum.com/news/azs-new-cancer-drugs-drive-another-stellar-quarter/
Zolgensma hits the ground running, says NovartisNovartis’ Zolgensma gene therapy for spinal muscular atrophy is the most expensive drug in the world, but that Share XZolgensma hits the ground running, says Novartishttps://pharmaphorum.com/news/zolgensma-hits-the-ground-running-says-novartis/
Federal opioid trial averted by last-ditch settlementTeva and three pharma wholesalers have agreed a $260 million settlement with two Ohio counties over their role Share XFederal opioid trial averted by last-ditch settlementhttps://pharmaphorum.com/news/federal-opioid-trial-averted-by-last-ditch-settlement/
Hall & Partners appoints Stacy Vaughn to senior US health roleHall & Partners Health has appointed Stacy Vaughn as managing partner of its US healthcare team, one of Share XHall & Partners appoints Stacy Vaughn to senior US health rolehttps://pharmaphorum.com/news/hall-partners-stacy-vaughn-beth-stagg/
Expect more M&A as Gilead names Dickinson as finance chief, say analystsGilead Sciences has named head of corporate development and strategy Andrew Dickinson as its new chief financial officer Share XExpect more M&A as Gilead names Dickinson as finance chief, say analystshttps://pharmaphorum.com/news/expect-more-ma-as-gilead-names-dickinson-as-finance-chief-say-analysts/
W2O acquires med comms agency Arcus MedicaHealthcare marketing communications agency W2O has acquired Philadelphia’s Arcus Medica to boost its scientific and med comms offering. Share XW2O acquires med comms agency Arcus Medicahttps://pharmaphorum.com/news/w2o-med-comms-agency-arcus-medica/
Guido Körfer and Marc Henschel join McCann Health GermanyPictured from left: Guido Körfer, Effie Baoutis and Marc Henschel McCann Health Germany has made two key appointments Share XGuido Körfer and Marc Henschel join McCann Health Germanyhttps://pharmaphorum.com/news/korfer-henschel-mccann-health-germany/
